NovoCure (NVCR) EBITDA Margin (2014 - 2026)
NovoCure (NVCR) posted quarterly EBITDA Margin of 5.75% for Q2 2026, up 1913.0% year-on-year from 0.29% in Q2 2025, and up 85.15% on a QoQ basis from 38.73% in Q1 2026.
NovoCure (NVCR) EBITDA Margin (2014 - 2026) Analysis & Trends
NovoCure (NVCR) has reported EBITDA Margin for 13 consecutive years, with 5.75% the latest figure, recorded in Q2 2026.
- Quarterly EBITDA Margin rose 1913.0% year-over-year to 5.75% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 22.08% (up 534.0% YoY) and the FY2025 annual result came in at 23.47%, up 470.0% from the prior year.
- EBITDA Margin improved to 5.75% in Q2 2026 per NVCR's latest filing, from 38.73% in the prior quarter.
- Over the last five years, EBITDA Margin for NVCR reached as high as 0.59% in Q1 2022 and fell as low as 49.71% in Q2 2023.
- A 5-year average of 27.89% and a median of 24.66% in 2025 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin plunged 4872 bps — and 2024, when it soared 2738 bps.
- Year by year, EBITDA Margin stood at 33.46% in 2022, then declined by 16 bps to 38.66% in 2023, then dropped by 2 bps to 39.25% in 2024, then soared by 41 bps to 23.17% in 2025, then surged by 75 bps to 5.75% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 5.75%, 38.73%, and 23.17% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | NovoCure | 2.28 Bn | 1.85 Bn | 142.48 Mn | -5.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.75% |
| Mar 31, 2026 | -38.73% |
| Dec 31, 2025 | -23.17% |
| Sep 30, 2025 | -21.54% |
| Jun 30, 2025 | -24.89% |
| Mar 31, 2025 | -24.43% |
| Dec 31, 2024 | -39.25% |
| Sep 30, 2024 | -20.69% |
| Jun 30, 2024 | -22.33% |
| Mar 31, 2024 | -29.98% |
| Dec 31, 2023 | -38.66% |
| Sep 30, 2023 | -45.75% |
| Jun 30, 2023 | -49.71% |
| Mar 31, 2023 | -49.31% |
| Dec 31, 2022 | -33.46% |
| Sep 30, 2022 | -18.79% |
| Jun 30, 2022 | -15.00% |
| Mar 31, 2022 | -0.59% |
| Dec 31, 2021 | -17.56% |
| Sep 30, 2021 | -6.40% |